January's JPMorgan Healthcare Conference is expected to focus on M&A, AI-driven drug discovery and Chinese competition, per nearly a dozen biotech bankers, consultants and investors who spoke to Axios Pro.
Why it matters: Biotech's marquee event often shapes expectations for the year to come and provides a clear read on industry sentiment.
